n*********m
发帖数: 38 | 1 本人研制成功一个融合蛋白, 具有非常强的杀菌能力. 正在申请专利. 希望能产业化并
能开发更多的抗/杀耐药性细菌的融合蛋白以及功能蛋白药物.有兴趣的可以互相交流.
email:p*******[email protected] |
i****e
发帖数: 1527 | 2 Antimicrobial Peptide fused with GST or His Tag? |
n*********m
发帖数: 38 | 3 It's recombinant endolysin not antimicrobial peptide. It works for drug-
resistant S aureus. |
N****n
发帖数: 294 | 4 For in vivo? How about pharmakinetics, immune response? |
n*********m
发帖数: 38 | 5 No work has been done on in vivo, PK or immune response yet.
In my opinion, therapeutic protein drugs are more cleaner than small
chemical drugs in terms of side effect and drug residue, except immune
toxicity. Of course, there should be enough data to clear all these concerns
before it get in clinic application. |
o*****e
发帖数: 189 | 6 我想问个问题， 我不了解像你这样的产品到底要怎么判断它的可行性，以及将来的应
用性？ 比如说很多实验筛选出了很多抗癌药物， 公司到底是根据什么来判断拿哪个来
做临床？ 我表哥在国内投资了个医药公司，不久前就问过我这边如果发现了好的产品
，他们可以过来谈。但他们也才刚起来2年，估计也不怎么了解。 |
n*********m
发帖数: 38 | 7 I never worked in large-scale drug screen area. First, the lab data should
be solid, no twist in their interpretation. I remember that a big pharm (
Amgen?) found that only 5-6 chemicals showed some kind of effects from a
final most potential list of a large screen of chemicals that had been
claimed effective in publication.
The reason why drug is effective is that it is toxic. In toxicology, we
consider anything with toxic effect, depending on concentration and dose.
I think that, for any drug, the drug's effectiveness, specificity, and
toxicity should be considered before any clinical trial. All these factors
are related to sensitivity, either target cells' or non-target cells'. For
example, if a drug shows effect in high concentration, it may be not a good
candidate for further test because normally lab results are obtained with
cell-lines or relative homogeneous cells and the human body is composed of
heterogeneous cells. Different cells will have different sensitivity.
You need do all kinds of positive and negative control to confirm the
candidate that is superior comparing with existing drugs. You also need have
broad spectrum of data to demonstrate the acceptable side effects. |
d*****n
发帖数: 166 | 8 这个lysin阿，有个牛人在老鼠鼻子种了点菌,然后滴点lysin杀菌，
感觉不是很靠谱阿。
你这个会不会好点？
【在 n*********m 的大作中提到】
: It's recombinant endolysin not antimicrobial peptide. It works for drug-
: resistant S aureus.
|
o*****e
发帖数: 189 | 9
Thanks for your answer. You show your confidence with your product. Let's
keep in touch because my cousin just started his business two years ago, I
am not sure what kind of drug candidate they want and how they evaluate its
feasibility. Good luck with your patent.
【在 n*********m 的大作中提到】
: I never worked in large-scale drug screen area. First, the lab data should
: be solid, no twist in their interpretation. I remember that a big pharm (
: Amgen?) found that only 5-6 chemicals showed some kind of effects from a
: final most potential list of a large screen of chemicals that had been
: claimed effective in publication.
: The reason why drug is effective is that it is toxic. In toxicology, we
: consider anything with toxic effect, depending on concentration and dose.
: I think that, for any drug, the drug's effectiveness, specificity, and
: toxicity should be considered before any clinical trial. All these factors
: are related to sensitivity, either target cells' or non-target cells'. For
|
n*********m
发帖数: 38 | 10 I think so far there may be over hundred different lysins. I am not sure
which big bull you talked about. Is it Fischetti VA? No matter whom it is,
it's understandable that some are not effective in vivo. There are several
reasons. It's possible that the plate test results are not solid. It's also
possible that the condition for in vivo is not optimized.or other reasons.
This further reminds us that we need non-biased plate-test data and find the
best condition for each step further.
发信人: desitin (desitin), 信区: Biology
标 题: Re: 有人对产业化抗/杀菌酶感兴趣吗?
发信站: BBS 未名空间站 (Sat Jun 29 11:11:06 2013, 美东)
这个lysin阿，有个牛人在老鼠鼻子种了点菌,然后滴点lysin杀菌，
感觉不是很靠谱阿。
你这个会不会好点？ |
z********4
发帖数: 701 | 11 体内结果怎样？体外能抑菌的蛋白质很多，甚至硫酸氢氧化钠都能杀菌，关键是能否在
体内专一的起效。在体外用不如用噬菌体，还能自我繁殖，FDA批准过在食物上使用 |
n*********m
发帖数: 38 | 12 I have said in my second response that no work has been done in vivo yet.
Actually, not only H2SO2 and NaOH but also pure water can kill bacterial. If
you don't believe, you can put some bacterial in autoclaved H2O (without
any other chemicals) to see whether the germ will grow. But as a scientist,
we should know what's underlying.
I agree with you that the specificity will determine whether the protein
will be useful or not. The determinants for a protein enzyme to be a good
antibacterial are the bond the enzyme cleaves and the cell-wall binding
domain. Both of them take advantage of specific structure of bacterial cell
wall.
The beauty for protein antibacterials is not for in vitro or in vivo. It's
how we could develop specialized deliver approach for intracellular or
extracellular bacterials. That's also what we need further study.
Yes, FDA approved phage for food industry some time ago. Both are based on
the same principle but they have advantage and disadvantage respectively. |
b******n
发帖数: 4225 | 13 这个topic比较好
你觉得你的应用是在什么方面？食品保鲜，表面消毒还是感染治疗？
.
【在 n*********m 的大作中提到】
: 本人研制成功一个融合蛋白, 具有非常强的杀菌能力. 正在申请专利. 希望能产业化并
: 能开发更多的抗/杀耐药性细菌的融合蛋白以及功能蛋白药物.有兴趣的可以互相交流.
: email:p*******[email protected]
|
n*********m
发帖数: 38 | 14 It could be applied in all the perspectives you mentioned depending on the
bacterials and the lysins.
The most important thing is that you need find something novel, I mean there
is no traditional antibiotics for particular bacterial, such as MRSA, or
superior. For example, most small chemical antibiotics have some kind of
side effects. For a protein, if it has specific degrading enzyme activity
toward bacterial cell wall, the only concern I can think of is
immunotoxicity. |
